Skip to main content

Advertisement

SpringerLink
Log in

Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis

  • Review Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Chemotherapy-induced peripheral neuropathy (CIPN) is common and presents with persistent and challenging symptoms for which there is no effective means of prevention. This systematic review assessed the efficacy and safety of Goshajinkigan in the prevention of CIPN.

Methods

A comprehensive literature search was conducted using Scopus, Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and ICHUSHI. Randomised controlled trials comparing Goshajinkigan with an alternative strategy for preventing CIPN were selected.

Results

Of five studies included in the review, Goshajinkigan did not reduce the risk of CIPN when the common terminology criteria for adverse events was used [risk ratio (RR) 0.94, 95% confidence interval (CI) 0.57–1.57 for grade ≥2 CIPN and RR 1.08, 95% CI 0.59–2.00 for grade ≥3 CIPN]. When the neurotoxicity criteria of Debiopharm was used, Goshajinkigan tended to decrease the risk of CIPN, but not significantly (RR 0.74, 95% CI 0.33–1.64 for grade ≥2 CIPN and RR 0.65, 95% CI 0.28–1.52 for grade ≥3 CIPN).

Conclusions

Goshajinkigan tended to prevent persistence but not severity of CIPN. Higher quality trials using multiple measures are needed in the future to clarify the preventive effect of Goshajinkigan and to assess the various aspects of CIPN.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Chu SH, Lee YJ, Lee ES et al (2015) Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review. Support Care Cancer 23:513–524

    Article  PubMed  Google Scholar 

  2. Cioroiu C, Weimer LH (2017) Update on chemotherapy-induced peripheral neuropathy. Curr Neurol Neurosci Rep 17:47

    Article  PubMed  Google Scholar 

  3. Ewertz M, Qvortrup C, Eckhoff L (2015) Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol 54:587–591

    Article  PubMed  CAS  Google Scholar 

  4. Hershman DL, Till C, Wright JD et al (2016) Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group Clinical Trials. J Clin Oncol 34:3014–3022

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Mols F, Beijers T, Vreugdenhil G et al (2014) Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer 22:2261–2269

    Article  PubMed  Google Scholar 

  6. Hershman DL, Lacchetti C, Dworkin RH et al (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:1941–1967

    Article  PubMed  CAS  Google Scholar 

  7. Kono T, Hata T, Morita S et al (2013) Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy. Cancer Chemother Pharmacol 72:1283–1290

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Tawata M, Kurihara A, Nitta K et al (1994) The effects of goshajinkigan, a herbal medicine, on subjective symptoms and vibratory threshold in patients with diabetic neuropathy. Diabetes Res Clin Pract 26:121–128

    Article  PubMed  CAS  Google Scholar 

  9. Nishizawa M, Sutherland WH, Nukada H (1995) Gosha-jinki-gan (herbal medicine) in streptozocin-induced diabetic neuropathy. J Neurol Sci 132:177–181

    Article  PubMed  CAS  Google Scholar 

  10. Kono T, Mamiya N, Chisato N et al (2011) Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer. Evid Based Complement Altern Med 2011:418481

    Article  Google Scholar 

  11. Ushio S, Egashira N, Sada H et al (2012) Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents. Eur J Cancer 48:1407–1413

    Article  PubMed  CAS  Google Scholar 

  12. Shamseer L, Moher D, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 349:g7647

    Article  Google Scholar 

  13. Hoshino N, Hida K, Ganeko R et al (2017) Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy: protocol for a systematic review and meta-analysis. Int J Colorectal Dis 32:737–740

    Article  PubMed  Google Scholar 

  14. Inoue N, Ishida H, Sano M et al (2012) Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer. Int J Clin Oncol 17:341–347

    Article  PubMed  CAS  Google Scholar 

  15. Higgins JPT, Green S (editors) (2011) Cochrane Handbook for Systematic Review of Intervention 5. 1. 0. The Cochrane Collaboration

  16. Abe H, Kawai Y, Mori T et al (2013) The Kampo medicine Goshajinkigan prevents neuropathy in breast cancer patients treated with docetaxel. Asian Pac J Cancer Prev 14:6351–6356

    Article  PubMed  Google Scholar 

  17. Kawabata K, Nakano T, Tsutsumi J et al (2014) Reduction of paclitaxel-related peripheral sensory neuropathy by Gosha-jinki-gan or carbon dioxide feet and hand bathing (in Japanese). Jpn J Foot Care 12:145–150

    Google Scholar 

  18. Nishioka M, Shimada M, Kurita N et al (2011) The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. Int J Clin Oncol 16:322–327

    Article  PubMed  Google Scholar 

  19. Oki E, Emi Y, Kojima H et al (2015) Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. Int J Clin Oncol 20:767–775

    Article  PubMed  CAS  Google Scholar 

  20. Griffith KA, Merkies IS, Hill EE et al (2010) Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties. J Peripher Nerv Syst 15:314–325

    Article  PubMed  Google Scholar 

  21. Kolb NA, Smith AG, Singleton JR et al (2016) The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol 73:860–866

    Article  PubMed  Google Scholar 

  22. Smith EM, Pang H, Cirrincione C et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309:1359–1367

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Cascella M, Muzio MR (2017) Potential application of the Kampo medicine goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy. J Integr Med 15:77–87

    Article  PubMed  Google Scholar 

  24. Cremonini F (2014) Standardized herbal treatments on functional bowel disorders: moving from putative mechanisms of action to controlled clinical trials. Neurogastroenterol Motil 26:893–900

    Article  PubMed  CAS  Google Scholar 

  25. Brami C, Bao T, Deng G (2016) Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: a systematic review. Crit Rev Oncol Hematol 98:325–334

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study was funded by the Japan Society for the Promotion of Science (Grant no. 16K10538).

Author information

Authors and Affiliations

  1. Department of Surgery, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan

    Nobuaki Hoshino, Riki Ganeko, Koya Hida & Yoshiharu Sakai

Authors
  1. Nobuaki Hoshino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Riki Ganeko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koya Hida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshiharu Sakai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nobuaki Hoshino.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hoshino, N., Ganeko, R., Hida, K. et al. Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Int J Clin Oncol 23, 434–442 (2018). https://doi.org/10.1007/s10147-017-1229-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-017-1229-4

Keywords

Search

Navigation